Interview: Biocon's Chairman MD: Kiran Mazumdar-Shaw

Look forward to an IPO in next 18-24 months, says Biocon’s Kiran Mazumdar Shaw

Q2WithBQ With Biocon's Kiran Mazumdar Shaw

Profit Insights | Biocon's Kiran Mazumdar Shaw Exclusive | NDTV Profit

Biocon’s Kiran Mazumdar Shaw On Who’ll Win The Battle Between ‘Innovators’ And Biosimilar Makers

kiran-mazumdar-shaw-at-global-technology-summit

Q4 Review: Biocon's Kiran Mazumdar Shaw On Earnings & FY23 Projections

Kiran Mazumdar Shaw On Fighting and Recovering From COVID-19: ‘Dont Panic, Be Positive

Kiran Mazumdar Shaw of Biocon on biosimilar & business outlook

Safe place to be in if coronavirus mortality rate brought down: Kiran Mazumdar Shaw

Kiran Mazumdar-Shaw on why India needs to open up after May 3rd 

Kiran Mazumdar-Shaw | Philanthropic focus on research

Kiran Mazumdar Shaw of Biocon on business outlook

Kiran Mazumdar Shaw Backs Sikka & Team

Kiran Mazumdar Shaw: The entrepreneur ahead of her time

It's a very welcome move: Kiran Mazumdar-Shaw on WHO's nod for Covaxin

Shah Rukh Khan calls Kiran Mazumdar Shaw a role model (GOSSIP)

Kiran Mazumdar-Shaw | Advice to new philanthropists: where can you make a difference?

Kiran Mazumdar Shaw Explains The Meaning of Atmanirbharta

Kiran Mazumdar-Shaw | Philanthropy has to be sustainable

Kiran Mazumdar Shaw’s multi-billion dollar baby

Auto Expo 2020: Here's a look at MG Motor India's future ready portfolio

Here’s what restauranteurs make of Mumbai 24x7

Omar Abdullah's sister moves Supreme Court challenging his detention under the Public Safety Act

Totally false that ousted CEO Neumann left with $1 Bn, says WeWork's executive chairman Marcelo Claure

Indian ride hailing app Ola has rolled out its service in London

London High Court to hear Mallya extradition case from tomorrow

Biocon and HealthCare Global In Focus | Earnings Edge | NDTV Profit

Q1 Review: Biocon's Profit, Margins Fall; Misses Estimates

Q4 Review | Biocon March Quarter Net Profit Soars

Stocks In Focus: Biocon, CG Power and Industrials, LIC & More

Q2 Review: After Weak Q2, Can Biocon Bounce Back In Q3? | BQPrime

Biocon Withdraws Drug Application With EMA